hsv-1716
Biologicalexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT00931931)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Astrocytoma · Phase 1
- Chordoma · Phase 1
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Gliosarcoma · Phase 1
- Mesothelioma, Malignant · Phase 1/Phase 2
- Neoplasms · Phase 1
- Neuroblastoma · Phase 1
- Neurofibrosarcoma · Phase 1
- Oligodendroglioma · Phase 1
- Osteosarcoma · Phase 1
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1
- Sarcoma, Ewing · Phase 1
- Wilms Tumor · Phase 1
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hsv-1716
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02031965 | Phase 1 | Dec 1, 2013 | National Cancer Institute (NCI), Pediatric Brain Tumor Consortium |
| NCT01721018 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | Sheffield Hallam University, Sorrento Therapeutics, Inc. |
| NCT00931931 | Phase 1 | Mar 1, 2010 | Ohio State University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Sheffield Hallam University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Sorrento Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2012 |
5 organizations
Page 1 / 1